Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "mg"

1150 News Found

Redcliffe Labs sells Crysta IVF to MMG Group’s Moon Care to sharpen diagnostics play
Healthcare | April 09, 2026

Redcliffe Labs sells Crysta IVF to MMG Group’s Moon Care to sharpen diagnostics play

Divestment marks Redcliffe’s strategic pivot toward preventive and advanced diagnostics; Crysta IVF to continue under existing leadership


Amgen’s TEPEZZA injection clears Phase 3 trial with high efficacy
Clinical Trials | April 08, 2026

Amgen’s TEPEZZA injection clears Phase 3 trial with high efficacy

The trial also demonstrated significant improvements across multiple secondary endpoints


Bayer plans to offer Eylea 2mg at lower cost in India for benefit of retinal disease patients
News | April 02, 2026

Bayer plans to offer Eylea 2mg at lower cost in India for benefit of retinal disease patients

Eylea 2mg (intravitreal aflibercept injection) is an anti-VEGF therapy that blocks a protein responsible for abnormal blood vessel growth and leakage in the retina


MGM Healthcare builds world’s largest intestinal transplant program in 3 years
Hospitals | March 27, 2026

MGM Healthcare builds world’s largest intestinal transplant program in 3 years

Since launching, the hospital has performed over 40 intestinal transplants, including 21 in 2025 alone


MGM Hospitals deliver life-saving CAR-T therapy to elderly cancer patients in Chennai
News | March 05, 2026

MGM Hospitals deliver life-saving CAR-T therapy to elderly cancer patients in Chennai

A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer


Indoco Remedies receives final ANDA approval from USFDA for Brivaracetam Oral Solution, 10 mg/mL
Drug Approval | February 25, 2026

Indoco Remedies receives final ANDA approval from USFDA for Brivaracetam Oral Solution, 10 mg/mL

Brivaracetam Oral Solution (10 mg/mL) is a prescription antiepileptic drug (anticonvulsant) used for treatment of partial-onset seizures in patients 1 month of age and older


Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment
News | February 19, 2026

Zydus introduces ANYRA (Aflibercept 2 mg) for advanced retinal disease treatment

ANYRA is India’s first indigenously developed Aflibercept 2 mg biosimilar


Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg
Drug Approval | February 19, 2026

Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg

Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension


Amgen scores EU nod for UPLIZNA in rare autoimmune disease
News | February 16, 2026

Amgen scores EU nod for UPLIZNA in rare autoimmune disease

The approval marks a major advance in targeted treatment for this rare, chronic autoimmune disease, offering twice-yearly maintenance dosing after two initial loading doses


EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy
News | January 17, 2026

EU clears Eylea 8 mg for retinal vein occlusion, expanding use of long-acting eye therapy

Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike